Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.

@article{Fioranelli2017RisankizumabVU,
  title={Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.},
  author={Massimo Fioranelli and Maria Grazia Roccia and Torello Maria Lotti},
  journal={Dermatologic therapy},
  year={2017},
  volume={30 5}
}
Interleukin-23 stimulate T helper (Th) 17 cells, Th 22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) a. It plays a pivotal role in the pathogenesis of psoriasis. In the present study (Papp et al., 2017) the authors compared the effect of risankizumab, a humanized IgG1 monoclonal antibody that inhibits interleukin-23, and ustekinumab, an interleukin12 and interleukin-23 inhibitor, in patients with moderate-to-severe… CONTINUE READING